Literature DB >> 3247002

Ultrasonic vocalization in rat pups as a marker of behavioral development: an investigation of the effects of drugs influencing brain opioid system.

V Cuomo1, R Cagiano, M A De Salvia, P Restani, R Galimberti, S Colonna, G Racagni, C L Galli.   

Abstract

Early postnatal exposure to morphine significantly influenced the ultrasonic vocalization of rat pups removed from their nest. In particular, a significant decrease in the rate of calling, sound pressure level and range of frequency was found in morphine-treated animals; moreover, the duration of calls was significantly increased by morphine administration. Conversely, neither beta-casomorphins (beta CMS), which are opioid peptides derived from the enzymatic digestion of milk protein (beta-casein), nor an opioid antagonist, like naloxone, significantly affected ultrasonic emission. The results are discussed with particular reference to the role of the opioid system in separation distress-induced vocalization in young animals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3247002     DOI: 10.1016/0892-0362(88)90009-8

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  4 in total

1.  Ultrasounds emitted by female rats during agonistic interactions: effects of morphine and naltrexone.

Authors:  M Haney; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

2.  Morphine attenuates ultrasonic vocalization during agonistic encounters in adult male rats.

Authors:  J A Vivian; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Delta opioid receptors: reflexive, defensive and vocal affective responses in female rats.

Authors:  M Haney; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

4.  Ultrasounds during morphine withdrawal in rats.

Authors:  J A Vivian; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.